Market Failure, State Failure: The Political Economy of Supply Chain Strengthening to Ensure Equitable Access to Vaccines and Medicines in Low- and Middle-Income Countries.
Context: Much of the existing work on the political economy of vaccine access has focused on how intellectual property rights agreements contribute to inequitable COVID-19 vaccine access between high-income and low- and middle-income countries (LMICs). The two solutions that emerged to scale up acce...
| Publicado en: | Journal of Health Politics, Policy & Law Vol. 49; no. 1; pp. 43 - 73 |
|---|---|
| Autor principal: | |
| Formato: | Artículo |
| Publicado: |
Duke University Press
Feb2024
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=174300856&site=ehost-live header: @attributes: shortDbName: ssf uiTerm: 174300856 longDbName: Social Sciences Full Text (H.W. Wilson) uiTag: AN controlInfo: bkinfo: jinfo: jid: 03616878 HPP jtl: Journal of Health Politics, Policy & Law issn: 03616878 maglogo: N pubinfo: dt: Feb2024 vid: 49 iid: 1 pid: 154 pub: Duke University Press artinfo: ui: 174300856 10.1215/03616878-10910242 ppf: 43 ppct: 30 formats: tig: atl: Market Failure, State Failure: The Political Economy of Supply Chain Strengthening to Ensure Equitable Access to Vaccines and Medicines in Low- and Middle-Income Countries. aug: au: Fox, Ashley affil: University at Albany, State University of New York su: Investments Health services accessibility Practical politics Negotiation Manufacturing industries State governments Private sector Nonprescription drugs Intellectual property Responsibility Drugs Business Government policy Public sector Wages Deception Personnel management Economics Middle-income countries Vaccines Acquisition of property Medical supplies Supply chains Health care reform Low-income countries Pharmaceutical industry Drug storage Endowments sug: subj: Investments Health services accessibility Practical politics Negotiation Manufacturing industries State governments Private sector Nonprescription drugs Intellectual property Responsibility Drugs Business Government policy Public sector Wages Deception Personnel management Economics Pharmaceutical and medicine manufacturing Pharmaceuticals and pharmacy supplies merchant wholesalers Drugs and Druggists' Sundries Merchant Wholesalers Grantmaking Foundations Investment Advice Miscellaneous Financial Investment Activities Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers Professional machinery, equipment and supplies merchant wholesalers Human Resources Consulting Services Administration of Human Resource Programs (except Education, Public Health, and Veterans' Affairs Programs) Pharmaceutical Preparation Manufacturing Middle-income countries Vaccines Acquisition of property Medical supplies Supply chains Health care reform Low-income countries Pharmaceutical industry Drug storage Endowments keyword: access political economy supply chains vaccines access political economy supply chains vaccines ab: Context: Much of the existing work on the political economy of vaccine access has focused on how intellectual property rights agreements contribute to inequitable COVID-19 vaccine access between high-income and low- and middle-income countries (LMICs). The two solutions that emerged to scale up access in LMICs involved either voluntary arrangements under COVAX or a waiver of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) to allow immediate access to intellectual property. However, an additional constraint on access is weak and ineffective supply chains within LMICs that have eroded over several decades of health-sector reform. Methods: This article reviews the literature on the political economy of supply chain strengthening in LMICs and identifies key challenges to equitable access to emergent vaccines and other medicines emanating from market and state failures in internal supply chains. Findings: Over the past century, supply chain policies in LMICs have alternated among an emphasis on addressing market failures contributing to unaffordability of vaccines/medicines, an emphasis on state failures contributing to unavailability of vaccines/medicines, and a more recent move toward public-private hybrid arrangements to strengthen supply chains. Conclusions: In addition to reshoring production capacity through a TRIPs waiver, the international community must address chronic weakness in internal supply chains in LMICs to ensure access to novel vaccines/medicines. pubtype: Academic Journal doctype: Article src: R language: English refInfo: copyright: @attributes: flag: N holdings: @attributes: islocal: N |
|---|